Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback